Investor Presentation H1 2023

8 Investor presentation First six months of 2023 GLP-1 class expansion accelerates in the US in the first half of 2023 with volume growth across our portfolio US GLP-1 weekly NBRx prescriptions Weekly NBRX scripts ('000s) 00 90 60 60 30 0 Jul 2021 Ozempic Rybelsus® Novo NordiskⓇ US GLP-1 TRX market share TRX share Total GLP-1 scripts (millions) Class growth >60% 60% 6 55.4% 5 44.5% 40% 4 20% 26.8% 3 17.0% 2 7.0% 1 4.0% 0% 0 Jul 2023 Jul 2021 Jul 2023 VictozaⓇ NN GLP-1 - dulaglutide tirzepatide Total monthly GLP-1 scripts NBRX: New-to-brand prescriptions; TRX: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q2 2023 vs Q2 2022 Source: IQVIA Xponent, NBRx data from week ending 21 Jul 2023. TRx data from week ending 21 Jul 2023. Each data points represents a rolling four-week average

View entire presentation